The panel screened includes major GPCR targets (dopaminergic, serotonergic, opioid, cannabinoid, etc.), monoamine transporters (DAT, NET, SERT), and other well-known targets involved in pain and other CNS disorders. Here, SLC6A3 is linked to central nervous system disorder.